Regeneron Pharmaceuticals (REGN) Posts Q4 Loss of 37c/Share
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $896.82 +0.32%
Revenue Growth %: +2.2%
Financial Fact:
Research and development: 543.05M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +2.2%
Financial Fact:
Research and development: 543.05M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q4 EPS of ($0.37), $0.23 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $123 million versus the consensus estimate of $131.04 million.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Oilfield firm SLB's profit rises on international drilling demand
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
